FHD-286
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Uveal Melanoma
Conditions
Metastatic Uveal Melanoma
Trial Timeline
May 11, 2021 → Nov 30, 2023
NCT ID
NCT04879017About FHD-286
FHD-286 is a phase 1 stage product being developed by Foghorn Therapeutics for Metastatic Uveal Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04879017. Target conditions include Metastatic Uveal Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Uveal Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04879017 | Phase 1 | Terminated |
Competing Products
20 competing products in Metastatic Uveal Melanoma